규제 업데이트
FDA, EMA, TGA 및 글로벌 규제 동향
규제 업데이트
2026년 9월 3일•1분 읽기
Temporary Reimbursement Granted for Pediatric Smectite After Indication Removal
Korean Pharmaceutical Association secured a three‑day temporary reimbursement for di‑octahedral smectite dispensed to patients under 19, easing pharmacy billing concerns after pediatric indication was withdrawn.
1
규제 업데이트
2026년 9월 3일•1분 읽기
Korean Pharmacist Group Calls for Further Revisions to OTC Standard Manufacturing Criteria
The Korean Ministry of Food and Drug Safety announced a partial amendment to OTC drug manufacturing standards; a pharmacist association praised the move but urged broader, realistic updates.
규제 업데이트
2026년 9월 3일•1분 읽기
FDA Approves ANDA084231 for Methocarbamol 500 mg Oral Tablet
The FDA approved ANDA084231 for a 500 mg methocarbamol tablet submitted by Puracap Pharm; the product is currently listed as discontinued.
규제 업데이트
2026년 9월 3일•1분 읽기
FDA Approves Actavis Labs Metoprolol Succinate Extended‑Release Tablets (ANDA 076862)
Actavis Labs FL Inc received FDA approval for its metoprolol succinate extended‑release tablets under ANDA 076862, covering a prescription 50 mg product and a discontinued 25 mg product.
규제 업데이트
2026년 9월 3일•1분 읽기
FDA Approves ANDA 076576 for Sotalol Hydrochloride Tablets by Sun Pharm Industries
The FDA approved application ANDA076576 for oral Sotalol Hydrochloride tablets (80 mg, 120 mg, 160 mg) from Sun Pharm Industries; all listed products are marked discontinued.
규제 업데이트
2026년 9월 3일•1분 읽기
FDA Approves ANDA083606 for Butabarital Sodium Oral Tablet
The FDA approved ANDA083606 for an oral tablet of butabarital sodium (16.2 mg) submitted by Solvay; the product is listed as discontinued.
규제 업데이트
2026년 9월 3일•1분 읽기
DICOPAC KIT
FDA NDA017406 for DICOPAC KIT, sponsored by GE Healthcare, indicates the product is discontinued and lists its submission history and active ingredients.
규제 업데이트
2026년 9월 3일•1분 읽기
FDA Approves Cipla Cetirizine Allergy Tablets (ANDA077318)
FDA has approved Cipla Ltd.'s ANDA077318 for two oral cetirizine hydrochloride allergy tablets (5 mg and 10 mg), both listed as discontinued.
규제 업데이트
2026년 9월 3일•1분 읽기
2027 Minimum Wage Set at 17,000 KRW per Hour
South Korea's Minimum Wage Committee approved a 3.68% increase, setting the 2027 hourly minimum wage at 17,000 KRW.
규제 업데이트
2026년 9월 3일•1분 읽기
MHRA publishes field safety notices for medical devices (24‑28 Aug 2026)
The UK Medicines and Healthcare products Regulatory Agency listed several field safety notices for devices such as femoral head adapters, infusion pump cassettes and fluoroscopic X‑ray systems between 24‑28 August 2026.
규제 업데이트
2026년 9월 3일•1분 읽기
FDA Approves Apotex CILOSTAZOL (ANDA077030)
FDA has approved Apotex's oral cilostazol tablets (50 mg and 100 mg) under ANDA 077030, adding a generic phosphodiesterase‑3 inhibitor to the market.
규제 업데이트
2026년 9월 3일•1분 읽기
FDA Approves ECONOPRED Ophthalmic Suspension (NDA 017468) – Discontinued
The FDA approved ECONOPRED, a 0.125% prednisolone acetate ophthalmic suspension, under NDA 017468 with multiple manufacturing submissions and a 2003 labeling approval. The product is now listed as discontinued.